Clinical trials: Pandemic
COVID-19 Pandemic
A Phase I Study to Evaluate Safety, Tolerability, and Immunogenicity of a PIKA COVID-19 Vaccine in Healthy Individuals
This is a Phase I, open label, dose-escalation study of three dose levels of the SARS-CoV-2 spike antigen administered intramuscularly (IM) in combination with a fixed dosage of PIKA adjuvant vaccine to evaluate the safety…
- Trial name
- NCT05305300
- Testing
- PIKA COVID-19 Vaccine (CHO cell, S-protein), Arm A, PIKA COVID-19 Vaccine (CHO cell, S-protein), Arm B
- Where
- United Arab Emirates
- Volunteers
- 135 people, healthy volunteers welcome
- Sponsor
- Yisheng Biopharma (Singapore) Pte. Ltd.
COVID-19 Pandemic
SARS-CoV-2 OTC At Home Test
The objective of this study is to evaluate the 3EO Health COVID-19 Test in individuals presenting at a medical facility. In eligible subjects, nasal samples will be collected for use with the 3EO Health COVID-19 Test, which will…
- Trial name
- NCT05553964
- Testing
- In Vitro
- Where
- 5 sites in United States
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- 3EO Health
COVID-19 Pandemic
A Preliminary Exploratory Study to Evaluate the Safety and Immunogenicity of Omicron Variant Bivalent Vaccine V-01-B5
It is a single center, randomized, open-labeled, exploratory clinical study to evaluate the safety and immunogenicity of Recombinant SARS-CoV-2 Fusion Protein bivalent Vaccine V-01-B5 as a second booster in adults aged 18-59…
- Trial name
- COVID-19 (NCT05585567)
- Testing
- V-01/V-01-B5, V-01-351/V-01-B5, V-01
- Where
- China
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Livzon Pharmaceutical Group Inc.
COVID-19 Pandemic
Exploratory Clinical Study to Evaluation of the Safety and Immunogenicity of Bivalent Vaccine V-01D-351
It is a single center, randomized, open-labeled, blind endpoint evaluation, exploratory clinical study to evaluate the safety and immunogenicity of bivalent vaccine V-01D-351 as a booster.
- Trial name
- COVID-19 (NCT05583357)
- Testing
- V-01D-351, CoronaVac
- Where
- China
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Livzon Pharmaceutical Group Inc.
COVID-19, COVID-19 Pandemic
Accelerating COVID-19 Clinical Recovery in the Outpatient Setting: Retrospective Analysis
The purpose of this retrospective study is to evaluate the effectiveness of CPM nasal spray as part of the treatment of COVID-19 and its impact on clinical symptoms. Two cohort groups will be compared (CPM vs. standard care).
- Conditions
- COVID-19, COVID-19 Pandemic, COVID-19 Respiratory Infection, SARS CoV 2 Infection
- Trial name
- ACCROS-R (NCT05520944)
- Testing
- ClorNovir® (Chlorpheniramine) 0.4% Nasal Spray
- Where
- Dominican Republic
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- Dr. Ferrer BioPharma
COVID-19 Virus Infection, COVID-19
Evaluation of Clinical Performance and Usability of iStatis COVID-19 Ag Rapid Test at POC
A rapid point of care test for the detection of virus particles will be compared to the FDA approved EUA RT-PCR detection standard.
- Conditions
- COVID-19 Virus Infection, COVID-19, Coronavirus Disease-19, COVID-19 Pandemic
- Trial name
- NCT05514691
- Testing
- iStatis COVID-19 Ag Rapid Test, "COVID-19 RT-PCR Test EUA Number: EUA200011, Company: Laboratory Corporation of America ("Labcorp")
- Where
- 2 sites in United States
- Volunteers
- 129 people, healthy volunteers welcome
- Sponsor
- bioLytical Laboratories
2019 Novel Coronavirus Disease, 2019 Novel Coronavirus Infection
Evaluation of the AudibleHealth Dx AI/ML-Based Dx SaMD Using FCV-SDS in the Diagnosis of COVID-19 Illness: Clinical Validation
The AudibleHealth Dx is a diagnostic software as a medical device (Dx SaMD) consisting of an ensemble of software subroutines that interacts with a proprietary database of Signal Data Signatures (SDS), using Artificial…
- Conditions
- 2019 Novel Coronavirus Disease, 2019 Novel Coronavirus Infection, 2019-nCoV Disease, COVID-19 Pandemic
- Trial name
- NCT05364268
- Testing
- Diagnostic Test: Diagnostic Software as Medical Device
- Where
- United States
- Volunteers
- 514 people, healthy volunteers welcome
- Sponsor
- AudibleHealth AI, Inc.
COVID-19 Pandemic
Oral Neutralizing Antibody Booster for Post-vaccinated People With COVID19 Vaccine
This is a study trial to assess the effectiveness of the immune response stimulated by the genetically engineered Bacillus subtilis spore extract which contain Spike protein of the SARS-COV2 on the spore coat.
- Trial name
- NCT05158855
- Testing
- Bacillus subtilis spore extract
- Where
- Macau
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- DreamTec Research Limited
COVID-19 Pandemic
Intranasal INNA-051 for Prevention of COVID-19 in Adults
This is a Phase 2, randomized, double-blind, placebo-controlled study of INNA-051 in adults following household contact with an individual with RT-PCR confirmed SARS CoV-2 infection.
- Trial name
- NCT05118763
- Testing
- INNA-051
- Volunteers
- healthy volunteers welcome
- Sponsor
- ENA Respiratory Pty Ltd
COVID-19 Pandemic
Immunogenicity and Safety of Sequential Immunization of Recombinant SARS-CoV-2 Fusion Protein Vaccine
A Randomized, Double Blind, Positive Control Clinical Study to Evaluate the Immunogenicity and Safety of Sequential Immunization of Recombinant SARS-CoV-2 Fusion Protein Vaccine (V-01) Against COVID-19 in Healthy Adults Aged 18…
- Trial name
- COVID-19 (NCT05238649)
- Testing
- Recombinant SARS-CoV-2 Fusion Protein Vaccine 10μg, Recombinant SARS-CoV-2 Fusion Protein Vaccine 25μg, SARS-Cov-2 Vaccine Inactivated
- Where
- China
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Livzon Pharmaceutical Group Inc.
COVID-19 Pandemic
The Immunogenicity and Safety of V-01-351/V-01D Bivalence Vaccine
It is a Single Arm, Open Label Clinical Study to Evaluate the Immunogenicity and Safety of Sequential Immunization of V-01-351/V-01D Bivalence Vaccine in Healthy Adults Aged 18 Years and Older After the Vaccination of 2 Doses of…
- Trial name
- Omicron (NCT05273528)
- Testing
- Recombinant SARS-CoV-2 Beta Variant Fusion Protein Vaccine/Recombinant SARS-CoV-2 Delta Variant Fusion Protein Vaccine
- Where
- China
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Livzon Pharmaceutical Group Inc.
COVID-19, COVID-19 Pandemic
PROlectin M, a Nucleocapsid TErminal GaleCTin Antagonist for COVID-19
A galectin antagonist prevents viral entry of Sars-CoV-2 virus by blocking the specific terminal on the surface receptors that enables the virus to enter human cells.
- Conditions
- COVID-19, COVID-19 Pandemic, COVID-19 Respiratory Infection, SARS-CoV2 Infection
- Trial name
- PROTECT (NCT05096052)
- Testing
- Galactomannan
- Volunteers
- 408 people
- Sponsor
- Bioxytran Inc.
COVID-19 Pandemic
Recombinant SARS-CoV-2 Fusion Protein Vaccine Booster Immunization Study to Evaluate the Safety and Immunogencity
A Clinical Study to Evaluate the Safety and Immunogenicity of Sequential Immunization of Recombinant SARS-CoV-2 Fusion Protein Vaccine (V-01) in Healthy Adults Aged 18 Years and Older After the Vaccination of 2 Doses of…
- Trial name
- COVID-19 (NCT05239832)
- Testing
- Recombinant SARS-CoV-2 Fusion Protein Vaccine
- Where
- China
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- Livzon Pharmaceutical Group Inc.
Pandemic Influenza
A/H5N1/LT Dose Ranging Study
This is a Phase 2, randomized, blinded, clinical trial. Up to 500 eligible subjects will be enrolled and randomized in a 1:2:2:1:2:2 ratio into one of six groups, and vaccinated in this study.
- Trial name
- NCT00908687
- Testing
- A/H5N1, LT Adjuvant Patch
- Where
- 6 sites in United States
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- Intercell USA, Inc.
COVID-19 Pandemic
Clinical Study for Recombinant SARS-CoV-2 Fusion Protein Vaccine (V-01) Booster Immunization
A Clinical Study to Evaluate the Immunogenicity and Safety of Sequential Immunization of Recombinant SARS-CoV-2 Fusion Protein Vaccine (V-01) Against COVID-19 in Healthy Adults Aged 18 Years and Older After the Vaccination of 2…
- Trial name
- COVID-19 (NCT05125874)
- Testing
- Recombinant SARS-CoV-2 Fusion Protein Vaccine
- Where
- China
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- Livzon Pharmaceutical Group Inc.
Pandemic Influenza Disease
Safety, Tolerability and Immunogenicity of Two Doses of Adjuvanted Monovalent Influenza Vaccine Administered to Healthy Adult and Elderly Subjects
The present study, phase III, randomized, controlled, observer-blind, multicenter study, will evaluate safety, tolerability and immunogenicity of two doses of an adjuvanted monovalent influenza vaccine compared with an adjuvanted…
- Trial name
- NCT00841763
- Testing
- Trivalent influenza virus vaccine (TIV), Adjuvanted monovalent influenza virus vaccine (aH5N1), Adjuvanted trivalent influenza virus vaccine (aTIV)
- Where
- 2 sites in Finland, Germany
- Volunteers
- 3,647 people, healthy volunteers welcome
- Sponsor
- Novartis
Pandemic Influenza
Immunogenicity, Safety and Tolerability of Two Doses of Adjuvanted and Non-adjuvanted Swine Origin A/H1N1 Monovalent Influenza Vaccine in Healthy Subjects 18 or More Years of Age
This present study, randomized, single-blind, dose-ranging, multicenter study, will evaluate immunogenicity, safety and tolerability of two doses of an adjuvanted and not-adjuvanted new swine-origin influenza A/H1N1 virus…
- Trial name
- NCT00971906
- Testing
- Monovalent A/H1N1 influenza vaccine
- Where
- 4 sites in Belgium, Germany and 1 more
- Volunteers
- 660 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines
Pandemic Influenza Prevention
A Phase 4 Post-marketing Study of Intramuscular Injections of BLB-750 in Healthy Adult Subjects
The purpose of this study is to evaluate the immunogenicity and safety of two intramuscular vaccinations with BLB-750 in healthy Japanese adults.
- Trial name
- NCT03370289
- Testing
- BLB-750 Vaccine (Qinghai RG strain)
- Where
- Japan
- Volunteers
- 55 people, healthy volunteers welcome
- Sponsor
- Takeda
Pandemic H5N1 Influenza
Safety and Immunogenicity of Two Doses of H5N1 Influenza Vaccine in Elderly Subjects
Evaluate Safety, Tolerability and Immune response of adjuvanted H5N1 cell culture derived influenza vaccine in elderly subjects
- Trial name
- NCT01766921
- Testing
- Adjuvanted H5N1 pandemic influenza vaccine
- Where
- 23 sites in United States, Australia and 2 more
- Volunteers
- 1,393 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines
Pandemic H5N1 Influenza
Safety and Immunogenicity of Two Doses of H5N1 Influenza Vaccine in Children
Evaluate Safety, Tolerability and Immune response of adjuvanted H5N1 cell culture derived influenza vaccine in children.
- Trial name
- NCT01776554
- Testing
- Adjuvanted H5N1 pandemic influenza vaccine
- Where
- 12 sites in United States, Thailand
- Volunteers
- 662 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines